ADVERTISEMENT
Videos
3-Year Results of the Zilver PTX Drug-Eluting Stent Trial
01/14/2013
Read an interview with Gary M. Ansel, MD, Dr. Dake's co-principal investigator, about the FDA approval of the Zilver PTX stent.
At the 2012 VEITHsymposium, investigators from the Zilver PTX trial presented 3-year results from the study. This study was the largest ever randomized trial for endovascular treatment of superficial femoral arterydisease with an endovascular device. Vascular Disease Management spoke with Michael Dake, MD, co-principal investigator of the study, about the results. He explained that 1- and 2-year results had been presented, and that these longer-term results were presented to show clinicians that the drug on the stent does not cause late phenomenon that limits its effectiveness. There were 479 patients, and patency was judged by ultrasound criteria. Dr. Dake explained that the results clearly show a significant difference for patency of the Zilver PTX stent versus a bare metal stent. Watch the video below for more.
